LLY in “GLP-1 Eats Everything”
Eli Lilly and Company
Supply-constrained franchise with pricing power.
LLY impact map — “GLP-1 Eats Everything”
How this story travels from the headline to LLY’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading LLY impact map…
Price history, marked with story events
Oct 8, 2025 – Oct 9, 2026 · 250 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Supply-constrained franchise with pricing power.
Read the full GLP-1 Eats Everything storyBull side
2 stories- Viewing
LLY in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Supply-constrained franchise with pricing power.
- China Becomes Pharma's Global R&D Engine
LLY in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Lilly can supplement its internal pipeline at attractive speed and cost through deals such as its acquisition of ex-China rights to Hengrui's investigational incretin program.
Bear side
1 story- America Imports the World's Drug Prices
LLY in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Its premium-priced, high-growth drug portfolio has substantial earnings sensitivity to lower US benchmark prices.